Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében

Júlia Gaál-Weisinger, Orsolya Mucsi, Gábor Körösmezey, Balázs Szili, Hanna Eid, Richárd Kiss, Csaba Bödör, Ilona Tárkányi, Zsolt Nagy, J. Demeter

Research output: Article

Abstract

The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.

Original languageHungarian
Pages (from-to)67-74
Number of pages8
JournalMagyar onkologia
Volume61
Issue number1
Publication statusPublished - márc. 8 2017

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Comorbidity
Therapeutics
Survival
Guidelines
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gaál-Weisinger, J., Mucsi, O., Körösmezey, G., Szili, B., Eid, H., Kiss, R., ... Demeter, J. (2017). Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében. Magyar onkologia, 61(1), 67-74.

Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében. / Gaál-Weisinger, Júlia; Mucsi, Orsolya; Körösmezey, Gábor; Szili, Balázs; Eid, Hanna; Kiss, Richárd; Bödör, Csaba; Tárkányi, Ilona; Nagy, Zsolt; Demeter, J.

In: Magyar onkologia, Vol. 61, No. 1, 08.03.2017, p. 67-74.

Research output: Article

Gaál-Weisinger, J, Mucsi, O, Körösmezey, G, Szili, B, Eid, H, Kiss, R, Bödör, C, Tárkányi, I, Nagy, Z & Demeter, J 2017, 'Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében', Magyar onkologia, vol. 61, no. 1, pp. 67-74.
Gaál-Weisinger J, Mucsi O, Körösmezey G, Szili B, Eid H, Kiss R et al. Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében. Magyar onkologia. 2017 márc. 8;61(1):67-74.
Gaál-Weisinger, Júlia ; Mucsi, Orsolya ; Körösmezey, Gábor ; Szili, Balázs ; Eid, Hanna ; Kiss, Richárd ; Bödör, Csaba ; Tárkányi, Ilona ; Nagy, Zsolt ; Demeter, J. / Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében. In: Magyar onkologia. 2017 ; Vol. 61, No. 1. pp. 67-74.
@article{a585553705fb4720acdd3bd164567520,
title = "{\'U}jdons{\'a}gok {\'e}s tapasztalatok a kr{\'o}nikus mieloid leuk{\'e}mia tirozinkin{\'a}z-g{\'a}tl{\'o} kezel{\'e}s{\'e}ben",
abstract = "The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.",
author = "J{\'u}lia Ga{\'a}l-Weisinger and Orsolya Mucsi and G{\'a}bor K{\"o}r{\"o}smezey and Bal{\'a}zs Szili and Hanna Eid and Rich{\'a}rd Kiss and Csaba B{\"o}d{\"o}r and Ilona T{\'a}rk{\'a}nyi and Zsolt Nagy and J. Demeter",
year = "2017",
month = "3",
day = "8",
language = "Hungarian",
volume = "61",
pages = "67--74",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Újdonságok és tapasztalatok a krónikus mieloid leukémia tirozinkináz-gátló kezelésében

AU - Gaál-Weisinger, Júlia

AU - Mucsi, Orsolya

AU - Körösmezey, Gábor

AU - Szili, Balázs

AU - Eid, Hanna

AU - Kiss, Richárd

AU - Bödör, Csaba

AU - Tárkányi, Ilona

AU - Nagy, Zsolt

AU - Demeter, J.

PY - 2017/3/8

Y1 - 2017/3/8

N2 - The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.

AB - The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.

UR - http://www.scopus.com/inward/record.url?scp=85066470132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066470132&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 67

EP - 74

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -